543 related articles for article (PubMed ID: 16130178)
1. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
[TBL] [Abstract][Full Text] [Related]
2. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
4. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
[TBL] [Abstract][Full Text] [Related]
5. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
Laporte R; Kohan A; Heitzmann J; Wisniewska H; Toy J; La E; Tariga H; Alagarsamy S; Ly B; Dykert J; Qi S; Wisniewski K; Galyean R; Croston G; Schteingart CD; Rivière PJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):786-96. PubMed ID: 21411496
[TBL] [Abstract][Full Text] [Related]
7. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
Stoev S; Cheng LL; Manning M; Wo NC; Szeto HH
J Pept Sci; 2006 Sep; 12(9):592-604. PubMed ID: 16625682
[TBL] [Abstract][Full Text] [Related]
9. The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations.
Guillon G; Derick S; Pena A; Cheng LL; Stoev S; Seyer R; Morgat JL; Barberis C; Gal CS; Wagnon J; Manning M
J Neuroendocrinol; 2004 Apr; 16(4):356-61. PubMed ID: 15089974
[TBL] [Abstract][Full Text] [Related]
10. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
Nakamura S; Yamamura Y; Itoh S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Ogawa H; Shinohara T; Kan K; Tanada Y; Teramoto S; Sumida T; Nakayama S; Sekiguchi K; Kambe T; Tsujimoto G; Mori T; Tominaga M
Br J Pharmacol; 2000 Apr; 129(8):1700-6. PubMed ID: 10780976
[TBL] [Abstract][Full Text] [Related]
12. Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells.
Perdonà E; Arban R; Griffante C
Eur J Pharmacol; 2012 Mar; 679(1-3):16-23. PubMed ID: 22285855
[TBL] [Abstract][Full Text] [Related]
13. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of F-180: a selective human V(1a) vasopressin receptor agonist of high affinity.
Andrés M; Trueba M; Guillon G
Br J Pharmacol; 2002 Apr; 135(7):1828-36. PubMed ID: 11934825
[TBL] [Abstract][Full Text] [Related]
15. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Terrillon S; Cheng LL; Stoev S; Mouillac B; Barberis C; Manning M; Durroux T
J Med Chem; 2002 Jun; 45(12):2579-88. PubMed ID: 12036367
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 1999 Nov; 5(11):472-90. PubMed ID: 10587312
[TBL] [Abstract][Full Text] [Related]
18. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.
Pena A; Murat B; Trueba M; Ventura MA; Bertrand G; Cheng LL; Stoev S; Szeto HH; Wo N; Brossard G; Serradeil-Le Gal C; Manning M; Guillon G
Endocrinology; 2007 Sep; 148(9):4136-46. PubMed ID: 17495006
[TBL] [Abstract][Full Text] [Related]
20. Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
Griffante C; Green A; Curcuruto O; Haslam CP; Dickinson BA; Arban R
Br J Pharmacol; 2005 Nov; 146(5):744-51. PubMed ID: 16158071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]